Detail
Článek
Článek online
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia

M. Stanulla, E. Dagdan, M. Zaliova, A. Möricke, C. Palmi, G. Cazzaniga, C. Eckert, G. Te Kronnie, JP. Bourquin, B. Bornhauser, R. Koehler, CR. Bartram, WD. Ludwig, K. Bleckmann, S. Groeneveld-Krentz, D. Schewe, SV. Junk, L. Hinze, N. Klein, CP....

. 2018 ; 36 (12) : 1240-1249. [pub] 20180302

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc19035372

Purpose Somatic deletions that affect the lymphoid transcription factor-coding gene IKZF1 have previously been reported as independently associated with a poor prognosis in pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). We have now refined the prognostic strength of IKZF1 deletions by analyzing the effect of co-occurring deletions. Patients and Methods The analysis involved 991 patients with BCP ALL treated in the Associazione Italiana Ematologia ed Oncologia Pediatrica-Berlin-Frankfurt-Muenster (AIEOP-BFM) ALL 2000 trial with complete information for copy number alterations of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B, Xp22.33/Yp11.31 (PAR1 region; CRLF2, CSF2RA, and IL3RA), and ERG; replication of findings involved 417 patients from the same trial. Results IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion conferred the worst outcome and, consequently, were grouped as IKZF1plus. The IKZF1plus group comprised 6% of patients with BCP ALL, with a 5-year event-free survival of 53 ± 6% compared with 79 ± 5% in patients with IKZF1 deletion who did not fulfill the IKZF1plus definition and 87 ± 1% in patients who lacked an IKZF1 deletion ( P ≤ .001). Respective 5-year cumulative relapse incidence rates were 44 ± 6%, 11 ± 4%, and 10 ± 1% ( P ≤ .001). Results were confirmed in the replication cohort, and multivariable analyses demonstrated independence of IKZF1plus. The IKZF1plus prognostic effect differed dramatically in analyses stratified by minimal residual disease (MRD) levels after induction treatment: 5-year event-free survival for MRD standard-risk IKZF1plus patients was 94 ± 5% versus 40 ± 10% in MRD intermediate- and 30 ± 14% in high-risk IKZF1plus patients ( P ≤ .001). Corresponding 5-year cumulative incidence of relapse rates were 6 ± 6%, 60 ± 10%, and 60 ± 17% ( P ≤ .001). Conclusion IKZF1plus describes a new MRD-dependent very-poor prognostic profile in BCP ALL. Because current AIEOP-BFM treatment is largely ineffective for MRD-positive IKZF1plus patients, new experimental treatment approaches will be evaluated in our upcoming trial AIEOP-BFM ALL 2017.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc19035372
003      
CZ-PrNML
005      
20250617120910.0
007      
ta
008      
191007s2018 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1200/JCO.2017.74.3617 $2 doi
035    __
$a (PubMed)29498923
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Stanulla, Martin $u Hannover Medical School
245    10
$a IKZF1plus Defines a New Minimal Residual Disease-Dependent Very-Poor Prognostic Profile in Pediatric B-Cell Precursor Acute Lymphoblastic Leukemia / $c M. Stanulla, E. Dagdan, M. Zaliova, A. Möricke, C. Palmi, G. Cazzaniga, C. Eckert, G. Te Kronnie, JP. Bourquin, B. Bornhauser, R. Koehler, CR. Bartram, WD. Ludwig, K. Bleckmann, S. Groeneveld-Krentz, D. Schewe, SV. Junk, L. Hinze, N. Klein, CP. Kratz, A. Biondi, A. Borkhardt, A. Kulozik, MU. Muckenthaler, G. Basso, MG. Valsecchi, S. Izraeli, BS. Petersen, A. Franke, P. Dörge, D. Steinemann, OA. Haas, R. Panzer-Grümayer, H. Cavé, RS. Houlston, G. Cario, M. Schrappe, M. Zimmermann, TRANSCALL Consortium, International BFM Study Group,
520    9_
$a Purpose Somatic deletions that affect the lymphoid transcription factor-coding gene IKZF1 have previously been reported as independently associated with a poor prognosis in pediatric B-cell precursor (BCP) acute lymphoblastic leukemia (ALL). We have now refined the prognostic strength of IKZF1 deletions by analyzing the effect of co-occurring deletions. Patients and Methods The analysis involved 991 patients with BCP ALL treated in the Associazione Italiana Ematologia ed Oncologia Pediatrica-Berlin-Frankfurt-Muenster (AIEOP-BFM) ALL 2000 trial with complete information for copy number alterations of IKZF1, PAX5, ETV6, RB1, BTG1, EBF1, CDKN2A, CDKN2B, Xp22.33/Yp11.31 (PAR1 region; CRLF2, CSF2RA, and IL3RA), and ERG; replication of findings involved 417 patients from the same trial. Results IKZF1 deletions that co-occurred with deletions in CDKN2A, CDKN2B, PAX5, or PAR1 in the absence of ERG deletion conferred the worst outcome and, consequently, were grouped as IKZF1plus. The IKZF1plus group comprised 6% of patients with BCP ALL, with a 5-year event-free survival of 53 ± 6% compared with 79 ± 5% in patients with IKZF1 deletion who did not fulfill the IKZF1plus definition and 87 ± 1% in patients who lacked an IKZF1 deletion ( P ≤ .001). Respective 5-year cumulative relapse incidence rates were 44 ± 6%, 11 ± 4%, and 10 ± 1% ( P ≤ .001). Results were confirmed in the replication cohort, and multivariable analyses demonstrated independence of IKZF1plus. The IKZF1plus prognostic effect differed dramatically in analyses stratified by minimal residual disease (MRD) levels after induction treatment: 5-year event-free survival for MRD standard-risk IKZF1plus patients was 94 ± 5% versus 40 ± 10% in MRD intermediate- and 30 ± 14% in high-risk IKZF1plus patients ( P ≤ .001). Corresponding 5-year cumulative incidence of relapse rates were 6 ± 6%, 60 ± 10%, and 60 ± 17% ( P ≤ .001). Conclusion IKZF1plus describes a new MRD-dependent very-poor prognostic profile in BCP ALL. Because current AIEOP-BFM treatment is largely ineffective for MRD-positive IKZF1plus patients, new experimental treatment approaches will be evaluated in our upcoming trial AIEOP-BFM ALL 2017.
650    _2
$a dítě $7 D002648
650    _2
$a inhibitor p15 cyklin-dependentní kinasy $x genetika $7 D050762
650    _2
$a inhibitor p16 cyklin-dependentní kinasy $x genetika $7 D019941
650    _2
$a ženské pohlaví $7 D005260
650    12
$a delece genu $7 D017353
650    _2
$a lidé $7 D006801
650    _2
$a transkripční faktor Ikaros $x genetika $7 D051740
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a reziduální nádor $x genetika $x patologie $7 D018365
650    _2
$a aktivátorový protein specifický pro B-buňky $x genetika $7 D051757
650    _2
$a pre-B-buněčná leukemie $x genetika $x patologie $7 D015452
650    _2
$a prognóza $7 D011379
650    _2
$a receptor PAR-1 $x genetika $7 D044463
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Dagdan, Elif $u Hannover Medical School
700    1_
$a Zaliova, Marketa $u Charles University and University Hospital Motol, Prague, Czech Republic
700    1_
$a Möricke, Anja $u University Hospital Schleswig-Holstein
700    1_
$a Palmi, Chiara $u Azienda Ospedaliera San Gerardo
700    1_
$a Cazzaniga, Giovanni $u Azienda Ospedaliera San Gerardo
700    1_
$a Eckert, Cornelia $u Charité University Hospital
700    1_
$a Te Kronnie, Geertruy $u University of Padova, Padua, Italy
700    1_
$a Bourquin, Jean-Pierre $u University Children's Hospital Zurich, Zurich, Switzerland
700    1_
$a Bornhauser, Beat $u University Children's Hospital Zurich, Zurich, Switzerland
700    1_
$a Koehler, Rolf $u University of Heidelberg, Heidelberg
700    1_
$a Bartram, Claus R., $d 1952- $u University of Heidelberg, Heidelberg $7 xx0333116
700    1_
$a Ludwig, Wolf-Dieter $u HELIOS-Clinic Berlin-Buch, Berlin
700    1_
$a Bleckmann, Kirsten $u University Hospital Schleswig-Holstein
700    1_
$a Groeneveld-Krentz, Stefanie $u Charité University Hospital
700    1_
$a Schewe, Denis $u University Hospital Schleswig-Holstein
700    1_
$a Junk, Stefanie V $u Hannover Medical School
700    1_
$a Hinze, Laura $u Hannover Medical School
700    1_
$a Klein, Norman $u Hannover Medical School
700    1_
$a Kratz, Christian P $u Hannover Medical School
700    1_
$a Biondi, Andrea $u Azienda Ospedaliera San Gerardo
700    1_
$a Borkhardt, Arndt $u Heinrich-Heine University, Düsseldorf, Germany
700    1_
$a Kulozik, Andreas $u University of Heidelberg, Heidelberg
700    1_
$a Muckenthaler, Martina U $u Hannover Medical School
700    1_
$a Basso, Giuseppe $u University of Padova, Padua, Italy
700    1_
$a Valsecchi, Maria Grazia $u University of Milano-Bicocca, Monza
700    1_
$a Izraeli, Shai $u Sheba Medical Center Tel-Hashomer and Tel Aviv University, Tel Aviv, Israel
700    1_
$a Petersen, Britt-Sabina $u Kiel University, Kiel
700    1_
$a Franke, Andre $u Kiel University, Kiel
700    1_
$a Dörge, Petra $u Hannover Medical School
700    1_
$a Steinemann, Doris $u Hannover Medical School
700    1_
$a Haas, Oskar A $u St Anna Kinderkrebsforschung and Medical University Vienna, Vienna, Austria
700    1_
$a Panzer-Grümayer, Renate $u St Anna Kinderkrebsforschung and Medical University Vienna, Vienna, Austria
700    1_
$a Cavé, Hélène $u Robert Debré Hospital and Paris-Diderot University, Paris, France
700    1_
$a Houlston, Richard S $u The Institute of Cancer Research, London, United Kingdom
700    1_
$a Cario, Gunnar $u University Hospital Schleswig-Holstein
700    1_
$a Schrappe, Martin $u University Hospital Schleswig-Holstein
700    1_
$a Zimmermann, Martin $u Hannover Medical School
710    2_
$a TRANSCALL Consortium
710    2_
$a International BFM Study Group
773    0_
$w MED00002596 $t Journal of clinical oncology $x 1527-7755 $g Roč. 36, č. 12 (2018), s. 1240-1249
856    41
$u https://pubmed.ncbi.nlm.nih.gov/29498923 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20191007 $b ABA008
991    __
$a 20250617120902 $b ABA008
999    __
$a ok $b bmc $g 1452032 $s 1073922
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2018 $b 36 $c 12 $d 1240-1249 $e 20180302 $i 1527-7755 $m Journal of clinical oncology $n J. clin. Oncol. $x MED00002596
LZP    __
$a Pubmed-20191007

Najít záznam

Citační ukazatele

Možnosti archivace